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Molecular Mechanism of the Activation-Induced Cell Death
Inhibition Mediated by a p70 Inhibitory Killer Cell Ig-Like
Receptor in Jurkat T Cells1
Yong-Joon Chwae,*† Mi Jung Chang,* Sang Myun Park,* Ho Yoon,‡ Hyun-Joo Park,*
Se Jong Kim,* and Jongsun Kim2*
In this study we investigated the molecular mechanism of the activation-induced cell death (AICD) inhibition mediated by a p70
inhibitory killer cell Ig-like receptor (KIR3DL1, also called NKB1) in Jurkat T cells. Using stable Jurkat transfectants that express
KIR or CD8-KIR fusion proteins we have shown for the first time that KIR inhibits, in a ligation-independent manner, the AICD
induced by PHA, PMA/ionomycin, or anti-CD3 Ab. The AICD inhibition mediated by KIR appears to result from the blockade
of Fas ligand induction upon activation of the Jurkat transfectants. Moreover, the membrane-proximal 20 aa of the KIR cyto-
plasmic tail were determined to play a crucial role in this process. Since the membrane-proximal portion of the KIR cytoplasmic
tail contains a putative protein kinase C (PKC) substrate site, we investigated the molecular interaction between KIR and PKC.
Immunoprecipitation analysis demonstrated that KIR constitutively bound both to PKC, a conventional Ca2-dependent PKC,
and to PKC, a novel Ca2-independent PKC. Furthermore, an in vitro kinase assay revealed that PKC activation was blocked
after PHA stimulation in Jurkat transfectants expressing KIR. These observations were supported by the finding that a recom-
binant KIR cytoplasmic tail also appeared to inhibit PKC activation in vitro. Taken together these data strongly suggest that KIR
inhibits the AICD of T cells by blocking Fas ligand induction upon stimulation, in a process that seems to be accomplished by PKC
recruitment to the membrane-proximal PKC binding site and subsequent inhibition of PKC activation against the activating
stimuli. The Journal of Immunology, 2002, 169: 3726–3735.
T he physiological functions of NK cells appear to be reg-ulated by a delicate balance between signals transmittedthrough activating receptors and inhibitory receptors on
the NK cell surface (1, 2). Inhibitory NK cell receptors (NKRs)3
that transmit an inhibitory signal to prevent NK cell-mediated cy-
totoxicity consist of two broad classes of membrane-anchored gly-
coproteins: the lectin-like receptors, including Ly49 receptors of
mice (3) and CD94/NKG2 of humans (4), and the Ig-like recep-
tors, including inhibitory killer cell Ig-like receptors (KIRs) (1, 2,
5) and Ig-like transcript molecules (also called leukocyte Ig-like
receptors) (6, 7). Most of the inhibitory NKRs are known to in-
teract with oligomeric determinants of class I MHC molecules on
target cells (1, 2).
Inhibitory KIRs are type I transmembrane glycoproteins and
consist of either two (for p58 KIR and KIR103: KIR2DLs) or three
(for p70 KIR: KIR3DLs) extracellular Ig-related domains, a trans-
membrane part, and a cytoplasmic tail (5). Inhibitory KIRs contain
one or two immunoreceptor tyrosine-based inhibition motifs
(ITIMs) within their cytoplasmic domain for the inhibitory signal
transduction. The protein tyrosine phosphatase Src homology 2 do-
main-containing protein tyrosine phosphatase-1/2 binds to tyrosine-
phosphorylated ITIMs and subsequently dephosphorylates multiple
signaling molecules that are involved in the early stage of activating
the signal transduction pathway (8, 9). As another signaling mecha-
nism operating through ITIM motifs, it has been suggested that the
phosphorylated form of p58 KIRs (also called KIR2DLs) binds to the
p85 subunit of phosphoinositol 3-kinase that may lead to activation
of the anti-apoptotic AKT kinase (10).
Although first characterized on NK cells, inhibitory KIRs (KIR
hereafter) are also found on subpopulations of  T cells (11–14).
Both CD4 and CD8  T cells express KIR, but KIRCD8
 T cells are much more commonly observed (15). Furthermore,
it has been reported that  T cells can also express KIR (16, 17).
KIR expressed on T cells have been shown to transmit an inhib-
itory signal that blocks the activating signals generated from TCR,
and this inhibitory signal, in turn, inhibits target cell cytolysis and
cytokine release (12, 13, 15, 17–23). A common feature of KIR
T cells is a cell surface phenotype that shares many characteristic
features with memory T cells. For example, KIR T cells lack CD28
and CD45RA, mostly express CD45RO, and express high levels of
CD18, CD44, CD29, and CD57 (18, 24). Like T cells belonging to the
effector memory T cell subset, KIR T cells do not express CCR7, a
chemokine receptor (25). Most importantly, recent studies have sug-
gested that KIR plays a role in the survival of memory phenotype T
cells (26, 27) and in the inhibition of T cell activation-induced cell
death (AICD) (26, 28). However, the exact mechanism of the AICD
inhibition mediated by KIR has not been revealed.
Activation of T lymphocytes via the TCR/CD3 complex leads to
the increased hydrolysis of phosphatidylinositol 4,5-biphosphate
and to the subsequent production of inositol 1,4,5-triphosphate and
diacylglycerol (DAG) that result in the elevation of intracellular
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calcium concentration and the activation of protein kinase C
(PKC), respectively (29, 30). PKC represents a family of serine/
threonine-specific protein kinases of which presently 11 different
PKC isoenzymes are known. On the basis of their structural and
biochemical properties they can be divided into three groups (31–
33): conventional PKC, including , 1, 2, and  isoenzymes;
novel PKC, including , , , and ; and atypical PKC, including
, 	, and 
. The activity of all PKC family members depends on the
presence of phosphatidylserine, and some of them require addi-
tional activators, such as DAG, Ca2, and phosphatidylinositol
4,5-triphosphate (34). The conventional PKC isoenzymes are ac-
tivated in a DAG- and calcium-dependent manner; novel PKC ac-
tivity is DAG dependent, but calcium independent (34), whereas
atypical PKC isoenzymes do not respond to DAG or calcium, but,
rather, are activated by other lipids, such as phosphatidylinositol-
3,4,5-triphosphate (35, 36).
Recognition of the MHC:antigenic peptide complex on APC by
Ag-specific TCR on T cells results in T lymphocyte activation,
cytokine secretion, and proliferation. Once the Ags have been
cleared by a series of immune responses, however, the activated T
lymphocytes are removed by apoptosis to maintain T cell ho-
meostasis (37). This form of apoptosis, known as AICD, is medi-
ated by the TCR-induced expression of Fas ligand (FasL). FasL
expressed on the activated T cell surface associates with Fas and
consequently induces T cell apoptosis (38–42). In addition to TCR
ligation, pharmacological drugs, such as phorbol ester and Ca2
ionophore, which mimic the two physiological signals (inositol
1,4,5-triphosphate and DAG, respectively) required for T cell ac-
tivation, can also induce FasL expression (43, 44) and AICD (45).
Phorbol ester is known to mediate the pleiotropic effects mainly
via the activation of PKC, and many lines of evidence suggest that
phorbol ester-sensitive PKC isoforms perform essential roles in the
FasL induction occurring during AICD (46–48).
In the present work we have investigated the molecular mech-
anism of the AICD inhibition mediated by KIR in Jurkat T cells.
Using stable Jurkat T cell lines expressing a series of deletion
mutant forms of a p70 KIR (KIR3DL1, also called NKB1), we
reveal that KIR inhibits the AICD of Jurkat T cells independent of
receptor ligation, and that the signaling mechanism of this obser-
vation is associated with the blockade of PKC activation through
the membrane-proximal 20 aa of the KIR cytoplasmic tail.
Materials and Methods
Cells, Abs, and other reagents
The human leukemic T cell line, Jurkat, was obtained from American Type
Culture Collection (Manassas, VA) and cultured in RPMI 1640 medium sup-
plemented with 10% heat-inactivated FCS, 2 mM L-glutamine, 100 U/ml pen-
icillin, and 100 g/ml streptomycin. Anti-CD8 (OKT8) and anti-CD3 mAbs
(OKT3) were purified from hybridoma cells using a protein A-Sepharose col-
umn. Anti-p70 KIR Ab (DX9) was purchased from BD PharMingen (San
Diego, CA), mouse anti-CD8 mAb (H-169) from Santa Cruz Biotechnology
(Santa Cruz, CA), rabbit anti-CD8 polyclonal Abs from Southern Biotechnol-
ogy (Birmingham, AL), apoptosis-inducing (CH11) anti-Fas mAb from Up-
state Biotechnology (Lake Placid, NY), blocking (ZB4) anti-Fas mAb from
MBL (Nagoya, Japan), and Anti-FasL mAb from BD PharMingen. Goat anti-
mouse IgG, PHA, PMA, protein A, and Geneticin were all obtained from
Sigma-Aldrich (St. Louis, MO). Ionomycin was purchased from Calbiochem
(La Jolla, CA), and GolgiStop was obtained from BD PharMingen. The re-
combinant protein of the p70 KIR cytoplasmic tail (KIR-cyt) was prepared as
previously described (49, 50).
Expression constructs and stable transfections
The whole protein-coding region of p70 KIR was amplified from pMET7-
NKB1 construct (51) by the PCR method and inserted into the EcoRI/
BamHI sites of the pcDNA 3.1 (Invitrogen, Carlsbad, CA). The fusion
constructs between the CD8 extracellular domain, the CD8 transmembrane
domain, and the p70 KIR cytoplasmic tail (pCD8KIR, pCD8KIRI, and
pCD8KIRII) were made by insertion of the PCR-amplified partial or
complete p70 KIR cytoplasmic tail sequences into the BglII/BamHI sites of
the pCD8T plasmid (52). The pCD8KIR construct encodes the whole pro-
tein-coding region of the p70 KIR cytoplasmic tail (aa 361–444), while the
pCD8KIRI construct encodes the whole region, except for the membrane-
proximal 20 aa residues (aa 381–444), and the pCD8KIRII construct
encodes only the membrane-proximal 37 aa residues (residues 361–397).
The sequences of all the constructs were verified by automatic DNA se-
quencing. Cells (1  107) were transfected with 10 g of each plasmid at
500 F/300 V using a Electroporator (BRL, Gaithersburg, MD) and were
selected in RPMI 1640 medium containing 1 mg/ml Geneticin for 2 wk.
Geneticin-resistant transfectants were tested for the expression of the p70
KIR or CD8-KIR fusion proteins by FACS and Western blot analysis.
Measurement of Jurkat cell size
Ten fields were randomly selected from each toluidine blue-stained smear
sample, from which the images of Jurkat were obtained using a digital
camera. The diameter of each cell was measured from digital images by
using an image analyzer (Optimas 6.1, Optima, Bothell, WA). The num-
bers of analyzed cells in the vector-transfected control and the p70 KIR-
expressing Jurkat clone (p701A1) were 647 and 722, respectively.
T cell stimulation and cell death analysis
For the induction of AICD, Jurkat T cell transfectants (5  105 cells/ml)
were stimulated with the indicated concentrations of either PHA for 12 h
or PMA (100 ng/ml) and ionomycin (1 g/ml) for 24 h. For the induction
of AICD by direct TCR cross-linking, Jurkat clones (5  105 cells/ml)
were incubated for 24 h in 24-well plates that had been sequentially coated
with 1 g/ml protein A overnight at 4°C and with OKT3 mAb (5 g/ml)
for 4 h at room temperature, respectively. In the Fas-mediated apoptosis
studies, Jurkat transfectants (5  105 cells/ml) were treated with anti-Fas
Ab CH11 (50 ng/ml) for the indicated time periods. Apoptotic cell fractions
were determined by annexin V-FITC (BioSource International, Camarillo,
CA) staining according to the manufacturer’s instruction and analyzed on
a FACScan (BD Biosciences, Lincoln Park, NJ).
Immunoprecipitation
Stimulated or unstimulated Jurkat transfectants (5  107 cells) were lysed
using 1 ml lysis buffer (10 mM Tris-HCl (pH 7.4) containing 150 mM
NaCl, 2 mM EDTA 1% Triton X-100, 1 mM PMSF, 15 g/ml leupeptin,
2 mM NaF, and 2 mM NaVO4) for 1 h at 4°C, then centrifuged for 15 min
at 3,000 rpm and subsequently for 30 min at 13,000 rpm at 4°C. The
supernatants were stored at 70°C. The cell lysates were precleared with
protein A/G-Sepharose (Pharmacia Biotech, Uppsala, Sweden) by incuba-
tion for 1 h at 4°C with constant agitation. The precleared lysates were then
incubated for 1 h with the appropriate Ab and protein A/G-Sepharose at
4°C. The immunoprecipitates were washed six times in the lysis buffer
described above. An aliquot of each sample was subjected to Western blot
analysis.
FasL mRNA expression analysis by RT-PCR
Jurkat stable transfectants (5  106 cells) were stimulated with PHA (3
g/ml) for 4 h, and total cellular RNAs were extracted using an RNeasy
mini kit (Qiagen, Santa Clarita, CA) and subjected to RT-PCR analysis of
FasL and hypoxanthine-guanine phosphoribosyltransferase as previously
described (53).
Flow cytometric detection of cell surface molecules
Staining for p70 KIR, CD8, and Fas was performed by incubating Jurkat
transfectants with saturating amounts of DX9, OKT8, and anti-Fas Ab,
respectively, in PBS containing 2% BSA for 30 min at 4°C. Expression
levels were measured on a FACScan (BD Biosciences) and were analyzed
using the WinMDI program (J. Trotter, Scripps Research Institute, La
Jolla, CA).
Flow cytometric detection of cytoplasmic FasL
The intracellular FasL content was measured in Jurkat T cell transfectants
both before and after stimulation in the presence of GolgiStop, an inhibitor
of protein secretion that results in the cytoplasmic accumulation of syn-
thesized FasL. After cell fixation and permeabilization, intracellular stain-
ing was performed according to the method described by Baars et al. (54).
Briefly, Jurkat T cells (5 105 cells/ml) were stimulated for 4 h with PHA
(3 g/ml) in the presence of GolgiStop. Then the cells were washed twice
in cold PBS containing 0.1% BSA and fixed with PBS containing 4%
paraformaldehyde for 5 min at 4°C. Fixation was followed by permeabi-
lization with PBS containing 0.1% saponin (Calbiochem) and 0.5% BSA.
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Nonspecific binding was blocked by incubating the cells in the same buffer
supplemented with 10% human serum for 20 min at 4°C. For all subse-
quent incubation and washing steps, PBS containing 0.1% saponin and
0.5% BSA was used. The cells were then washed once and stained with 5
g/ml anti-FasL Ab for 30 min at 4°C. After another washing step, the
cells were stained with FITC-labeled goat anti-mouse IgG mAb for 20 min
at 4°C. Expression levels of FasL were measured on a FACScan as de-
scribed above.
PKC kinase assay
The PKC kinase assay was performed using a SignaTECT PKC assay
system (Promega, Madison, WI) according to the manufacturer’s instruc-
tion with minor modifications. Briefly, PKC immunoprecipitates obtained
from 5  106 Jurkat cell transfectants were incubated with 100 M bio-
tinylated PKC-selective synthetic peptide (NH2-AAKIQASFRGHMA
RKK-COOH) in a kinase reaction buffer (20 mM Tris-HCl (pH 7.5), con-
taining 10 mM MgCl2, 0.25 mM EGTA, 0.4 mM CaCl2, 1 mg/ml BSA, 0.1
mM ATP, and 0.5 Ci [-32P]ATP) for either 10 min (PKC) or 30 min
(PKC) at 25°C in a final volume of 25 l. The reaction was stopped by
centrifugation at 3000  g for 5 min, which separated the immobilized
PKC immunoprecipitates from the soluble substrate. Supernatant (10 l)
from each sample was spotted onto SAM2RBiotin capture membrane and
washed four times with 2 M NaCl and four times with 2 M NaCl containing
1% phosphoric acid, and the incorporation of 32P into peptide was detected
by liquid scintillation counting.
Results
KIR expression inhibits the AICD of Jurkat T cells in a
ligation-independent manner
To investigate the effect of KIR on the AICD of T cells, a p70 KIR
(KIR3DL1, also called NKB1) full-length cDNA was stably trans-
fected to Jurkat T cells. The Jurkat T cell line has been widely used
as a good model of T cell AICD studies, since AICD can be easily
induced by various activating signals. Expression levels of p70
KIR in Jurkat transfectants were measured by FACS analysis (Fig.
1A), and three independent clones expressing the different KIR
levels were selected and used for AICD study of Jurkat T cells.
Compared with irrelevant Ab-stained control, surface expression
of KIR on clones p701A1, p702A6, and p704D2 was 3.87, 1.61,
and 1.56 times higher in mean fluorescence intensity, respectively.
We compared growth rates of the KIR-expressing clones with the
control clones and found that Jurkat cells expressing KIR grew at
a similar pace during the log phase, but reached the stationary
phase much faster with a lower cell density than the control cells
(Fig. 1B). The ratio of trypan blue-positive cells and trypan blue-
excluding cells was not significantly different between the two
groups. Interestingly, we also found that the KIR-expressing
clones appeared to be larger than either Jurkat cell line or control
clone transfected with empty vector (Fig. 1C). For reasons un-
known, KIR-expressing clones demonstrated greater forward scat-
ter values by FACS analysis (Fig. 1C, upper panel) and larger cell
sizes by image analysis (11.35 vs 8.54 m in diameter; p  0.01;
Fig. 1C, lower panel). These observations suggest that KIR might
constitutively transmit a certain signal that affects the cell size and
growth pattern of Jurkat cells.
The process of AICD can be mimicked in Jurkat T cells either
by cross-linking the TCR complex with anti-CD3 Ab or PHA or by
activating downstream signaling molecules, such as PKC and cal-
cineurin, with PMA in combination with a calcium ionophore
(ionomycin) (55–57). To induce AICD, we first stimulated the Jur-
kat clones (p701A1, p702A6, and p704D2) expressing KIR with
PHA and, surprisingly, found that these clones demonstrated much
less apoptotic cell death than Jurkat and control clones transfected
with empty vector (Fig. 2A). The differences in cell death patterns
between the control cells and the KIR-expressing Jurkat clones
were larger at lower PHA concentrations than at higher concen-
trations. Interestingly, the inhibitory effect of KIR on Jurkat AICD
appeared to be proportional to the KIR expression levels (Figs. 1A
and 2B). In addition, Jurkat cells expressing KIR showed lower
apoptotic cell death when AICD was induced by direct cross-link-
ing of TCR/CD3 complex (Fig. 2C).
Previous studies have suggested that cross-linking of KIR in-
hibits the target cell-lysis and IL-2 secretion of CTLs when CTLs
are stimulated (12, 13, 15, 17–23). To investigate the effect of KIR
cross-linking on the AICD of Jurkat T cells expressing KIR, the
Jurkat clone (p701A1) was pretreated with an anti-p70 KIR mAb
(DX9) and a cross-linking anti-mouse IgG Ab (goat anti-mouse
IgG) before PHA stimulation. Interestingly however, cross-linking
of KIR by DX9 did not affect the AICD inhibition mediated by
KIR (Fig. 3A). Furthermore, Jurkat T cell does not express HLA-B
FIGURE 1. Establishment of Jurkat stable cell lines expressing p70
KIR. A, Expression of p70 KIR on the surface of Jurkat clones. The pro-
tein-coding region of p70 KIR was cloned into pcDNA 3.1, and the re-
combinant DNA was stably transfected into Jurkat T cells. Among the
clones resistant to Geneticin, three independent clones expressing p70 KIR
on the surface were selected (p701A1, p702A6, and p704D2). Expression
levels were measured using FACS analysis with DX9 mAb. B, Growth
curves of the Jurkat clone expressing p70 KIR and the vector control.
Jurkat clone expressing p70 KIR (p701A1) or control clone transfected
with empty vector was seeded in 96-well plates at the concentration of 5
104 cells/ml, and total cell number was counted at the indicated times using
the trypan blue dye exclusion method. Similar results were obtained from
the other two clones (p702A6 and p704D2). C, Cell sizes of p70 KIR-express-
ing clone (p701A1) and the vector control. The upper panel shows forward
scatter (x-axis) and side scatter (y-axis) values of FACS analysis. The lower
panel shows pictures of Jurkat smears stained with toluidine blue.
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molecule (58, 59), the natural ligand of KIR used in this study
(KIR3DL1) (51). Therefore, it is highly likely that KIR functions
in a ligation-independent manner to inhibit T cell AICD. To con-
firm this observation, we made a CD8KIR fusion construct that
encoded the extracellular and transmembrane domains of the CD8
-chain and also the cytoplasmic tail of p70 KIR. Consistent with
the above result, the Jurkat clone (CD8KIR) expressing a CD8KIR
fusion protein appeared to be less sensitive to AICD regardless of
the incidence of receptor cross-linking with OKT8 Ab (Fig. 3B).
These results indicate that KIR expression inhibits AICD of Jurkat
T cells in a ligation-independent manner.
KIR expression protects Jurkat T cells from AICD via FasL
expression inhibition
It is well known that T cell AICD proceeds primarily via the in-
duction of FasL expression and subsequent Fas/FasL interaction
on the surface of activated T cells (39, 60). Therefore, the observed
inhibition of AICD by KIR expression could conceivably be me-
diated by any one of at least four nonexclusive mechanisms: the
inhibition of FasL expression, the inhibition of Fas receptor ex-
pression, the inhibition of apoptotic signaling events downstream
of Fas ligation, or the inhibition of a common apoptotic signaling
pathway. Firstly, the Fas expression level on the surface of the p70
KIR transfectants was analyzed by flow cytometry before and after
PHA stimulation. As shown in Fig. 4A, Fas expression was not
significantly changed in the Jurkat transfectants expressing KIR
compared with the control Jurkat cells, and the expression level
remained unchanged even after PHA stimulation. Secondly, to
evaluate whether the downstream apoptotic signaling events after
Fas ligation are defective in KIR transfectants, Fas-mediated apo-
ptosis of the Jurkat transfectants was induced by CH11, an anti-Fas
mAb. As shown in Fig. 4B, CH11 effectively induced apoptotic
cell death in the Jurkat transfectants expressing KIR as well as in
the control Jurkat cells. Interestingly, the Jurkat transfectants ex-
pressing KIR appeared to be more sensitive to the Fas-mediated
apoptosis. Thirdly, the Jurkat transfectants expressing KIR were
examined for defects along the common apoptotic signaling path-
way. For this purpose, a cytotoxic drug, cisplatin, was used to
induce apoptotic cell death, and it was found that KIR did not
affect the apoptosis mediated by cisplatin (Fig. 4C).
In the next step the expression level of FasL was analyzed by
RT-PCR and cytoplasmic FACS in the presence of GolgiStop, a
monesin-based inhibitor of protein secretion. Cytoplasmic FasL
FIGURE 2. Expression of KIR inhibits the AICD of Jurkat T cells. A,
AICD of Jurkat, vector control, or Jurkat clone expressing p70 KIR
(p701A1) was induced by the various concentrations of PHA. Jurkat cells
(5  105 cells) were placed in the 24-well plates, and PHA was added at
concentrations of 0, 1, 3, 5, 10 g/ml. After 12-h incubation, apoptotic cell
death ratios were determined using annexin V staining as described in
Materials and Methods. Similar results were obtained when the other two
KIR-expressing clones (p702A6 and p704D2) were used. B, The inhibitory
effect of the KIR expression on Jurkat AICD is proportional to the KIR
expression level. Three independent clones expressing different levels of
KIR were tested for AICD by treatment with PHA (3 g/ml). Results are
the mean  SD of three independent experiments, performed with duplicate
samples. C, KIR expression also blocks Jurkat AICD induced by TCR cross-
linking. See Materials and Methods for details. Results are the mean SD of
three independent experiments, performed with duplicate samples.
FIGURE 3. AICD inhibition in the Jurkat transfectants expressing KIR
is independent of receptor ligation. A, Effects of KIR cross-linking on the
PHA-induced AICD of Jurkat and the Jurkat clone expressing KIR. Jurkat
or Jurkat clone expressing KIR (p701A1) was incubated with or without
DX9, an anti-p70 KIR mAb (5 g/ml), and cross-linked with goat anti-
mouse IgG Ab (10 g/ml). After 12-h incubation, cell death was measured
as described in Materials and Methods. Similar results were observed from
the other clones expressing p70 KIR (p702A6 and p704D2). B, Effects of
CD8 cross-linking on the PHA-induced AICD of Jurkat clone expressing
the CD8KIR fusion protein. Jurkat clones transfected with either an empty
vector or the CD8KIR fusion construct were incubated with or without
OKT8 mAb (5 g/ml) and cross-linked with goat anti-mouse IgG Ab (10
g/ml). Cell death was induced by PHA (3 g/ml) and measured after 12-h
incubation. Each experiment was performed in duplicate with three inde-
pendent clones, and the result shown above is for one representative clone.
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expression was not detected before PHA stimulation in either the
control Jurkat cells or the Jurkat transfectants expressing KIR (data
not shown). After PHA (3 g/ml) treatment, FasL expression was
strongly induced in Jurkat T cells, whereas FasL induction in the
Jurkat transfectants expressing KIR was almost completely
blocked at both mRNA and protein levels (Fig. 5, A and B). Fi-
nally, a FasL blocking experiment was performed with anti-Fas
Ab. As expected, pretreatment of anti-Fas blocking Ab (ZB4) sig-
nificantly blocked the death of Jurkat cells in a dose-dependent
manner upon activation with PHA. In contrast, in the Jurkat trans-
fectants expressing KIR this effect was not observed (Fig. 5C).
Taken together these results clearly demonstrate that the inhibitory
effect of Jurkat AICD via KIR expression is mediated by the in-
hibition of FasL induction.
AICD induced by treatment with PMA and ionomycin was also
blocked in Jurkat transfectants expressing KIR
We showed that the AICD induced by PHA stimulation is signifi-
cantly inhibited in the Jurkat transfectants expressing KIR (Fig. 2) and
that the inhibition of AICD is mediated by blockage of the FasL
induction (Fig. 5). Similar phenomena were observed when AICD
was induced by the direct stimulation of TCR using anti-CD3 mAb
FIGURE 4. AICD inhibition in the Jurkat transfec-
tants expressing KIR is not associated with changes in
Fas expression level or with defects in the downstream
Fas signal. A, Fas expression of Jurkat and Jurkat trans-
fectants before and after PHA stimulation. Cells were
stimulated with PHA (3 g/ml) for 3 h, and changes in
Fas expression levels were checked by flow cytometry.
B, Fas-mediated apoptosis of Jurkat transfectants. Jurkat
transfectants were treated with CH11, an anti-Fas mAb
(50 ng/ml), for 12 h. Fas-mediated apoptosis was mea-
sured by annexin V staining as described in Materials
and Methods. C, Apoptosis of Jurkat transfectants in-
duced by cisplatin, a cytotoxic drug. Jurkat transfectants
(5 105 cells/ml) were treated with cisplatin of various
concentrations (0, 5, 10, and 20g/ml) for 24 h and then
tested for apoptotic cell death using annexin V staining
as described in Materials and Methods. The data repre-
sent the mean  SD of three independent experiments,
each performed in duplicate.
FIGURE 5. AICD inhibition in the Jurkat transfectants expressing KIR
is associated with inhibition of FasL induction. A, FasL mRNA expression
of Jurkat transfectants expressing KIR, Jurkat, and vector control before
and after PHA stimulation. Cells (4  106) were treated with PHA (3
g/ml) for 3 h, followed by FasL RT-PCR analysis performed as described
in Materials and Methods. The upper panel shows the PCR-amplified FasL
mRNA, and the lower panel shows the PCR-amplified control hypoxan-
thine-guanine phosphoribosyltransferase mRNA. B, Cytoplasmic FasL ex-
pression of Jurkat transfectants expressing KIR and Jurkat after PHA stim-
ulation. Cells (1  106) were pretreated with GolgiStop, a monesin-based
inhibitor of protein secretion, before PHA treatment (3 g/ml) for 3 h,
following which intracytoplasmic FasL staining was performed with anti-
FasL Ab as described in Materials and Methods. C, Blocking of AICD by
anti-Fas blocking Ab. Anti-Fas blocking Ab (ZB4) was pretreated for 1 h
at the indicated concentrations before PHA treatment (3 g/ml), and after
12 h apoptotic cell deaths were measured by annexin V staining as de-
scribed in Materials and Methods. The data are the mean  SD of three
independent experiments, performed in duplicate.
FIGURE 6. Jurkat clones expressing KIR are also resistant to PMA and
ionomycin-induced AICD. Jurkat, vector control, and Jurkat clones expressing
KIR were treated with or without either PMA (100 ng/ml) and ionomycin (1
g/ml) or an equivalent volume of DMSO (0.1%) as the solvent control. Ap-
optotic cell death was detected with annexin V staining as described in Ma-
terials and Methods. The data are the mean  SD of three independent ex-
periments using one representative clone among three Jurkat clones expressing
p70 KIR. The other two clones showed similar results.
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(Fig. 2C). In a first step toward understanding the molecular mecha-
nism underlying these observations, we investigated whether the Ju-
rkat transfectants expressing KIR would also exhibit resistance
against the AICD induced by PMA and ionomycin. PMA and iono-
mycin, known to be a PKC activator and a calcium ionophore, re-
spectively, have been widely used to bypass the early TCR signaling
pathway by direct stimulation of PKC and calcium signaling path-
ways in T cells (61). As shown in Fig. 6, when Jurkat transfectants
were stimulated with PMA (100 ng/ml) and ionomycin (1 g/ml),
those transfectants expressing KIR also exhibited significantly less
apoptotic cell death than the Jurkat control and the vector control
(12.90  0.28 vs 31.30  0.99 and 36.50  1.41%, respectively).
This suggests that the inhibition of Jurkat T cell AICD by KIR ex-
pression may result from the inhibition of PKC and/or the calcium
signaling pathway(s).
Membrane-proximal 20 aa of the KIR cytoplasmic tail are
responsible for KIR-mediated AICD inhibition
Considering the previous observation, the amino acid sequences
of the KIR cytoplasmic tails were re-examined. Interestingly, all
FIGURE 7. Membrane-proximal 20 aa of the KIR cytoplasmic tail are implicated in the KIR-mediated inhibition of AICD. A, Schematic diagrams of
CD8-KIR fusion constructs and their amino acid sequences of the cytoplasmic tail parts. The cDNAs encoding the CD8-KIR fusion proteins were subcloned
into pcDNA 3.1 and stably transfected into Jurkat T cells. In the lower panel, putative PKC phosphorylation sites are underlined, and ITIM motifs overlined.
B, Surface expression of the CD8-KIR fusion proteins. The expression levels of the CD8-KIR fusion proteins were determined by flow cytometry with
OKT8 mAb. C, PHA-induced AICD of Jurkat transfectants expressing CD8-KIR fusion proteins. D, PMA and ionomycin-induced AICD of Jurkat
transfectants expressing CD8-KIR fusion proteins. Jurkat clones expressing CD8-KIR fusion proteins were treated either with PHA (3 g/ml) for 12 h (C)
or with PMA (100 ng/ml) and ionomycin (1 g/ml) for 24 h (D). Apoptotic cell death fractions were measured by annexin V staining as described in
Materials and Methods. The data are mean  SD of three independent experiments.
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inhibitory KIR family members were found to have three putative
PKC phosphorylation sites in the cytoplasmic tails. The first is
located in the membrane-proximal region, and the other two are
between the two ITIMs (Fig. 7A). To determine which region of
the KIR cytoplasmic tail is responsible for the KIR-mediated
AICD inhibition in the Jurkat T cells, a series of CD8-KIR fusion
constructs was made (Fig. 7A). The CD8KIR construct encodes the
extracellular and transmembrane domains of CD8 and the cyto-
plasmic tail of p70 KIR. In the CD8KIRI construct, membrane-
proximal 20 aa, including the first putative PKC substrate site, are
absent. In the CD8KIRII construct, the carboxyl-terminal 51 aa,
including two ITIM motifs and two putative PKC substrate sites,
are absent. The fusion constructs were stably transfected into the
Jurkat, and clones expressing the CD8-KIR constructs were se-
lected by FACS analysis using an OKT8 mAb (Fig. 7B). Surpris-
ingly, the deletion of the membrane-proximal 20 aa, including the
first putative PKC substrate site, eliminated the inhibitory effect of
Jurkat AICD mediated by the KIR cytoplasmic tail in the Jurkat
transfectants expressing CD8KIRI (Fig. 7, C and D). In contrast,
Jurkat transfectants expressing CD8KIRII demonstrated similar
levels of apoptotic cell death as the CD8KIR transfectants (Fig. 7,
C and D). Taken together, these results indicate that the mem-
brane-proximal region (residues 361–381) in the p70 KIR cyto-
plasmic tail contains an important signaling motif that is respon-
sible for the ligation-independent inhibition of AICD, and that this
inhibitory effect may be associated with the inhibition of PKC or
the downstream signaling pathway of PKC.
PKC and PKC activation induced by PHA stimulation is
blocked in Jurkat transfectants expressing the p70 KIR
cytoplasmic tail
To elucidate the role of PKC in KIR-mediated AICD inhibition,
we first examined whether PKC is bound to the KIR cytoplasmic
tail before and after activation stimuli using immunoprecipitation
experiments. Among the various PKC isoforms, PKC and PKC
were chosen as representatives of conventional Ca2-dependent
PKC and novel Ca2-independent PKC, respectively. Immunopre-
cipitates prepared using anti-CD8 Abs from the CD8KIR and
CD8T Jurkat transfectants at various time points were resolved by
SDS-PAGE, and the gels were blotted with Abs of PKC and
PKC, respectively. As shown in Fig. 8, PKC and PKC consti-
tutively bound to the KIR cytoplasmic tail, and the binding did not
appear to be affected after activation stimuli.
Next, we investigated whether PKC could be normally activated
after PHA stimulation in the Jurkat transfectants expressing KIR.
An in vitro PKC kinase assay was performed using PKC and
PKC immunoprecipitates obtained from Jurkat and Jurkat trans-
fectants at various time intervals after PHA stimulation. In the
control Jurkat cells, PKC was activated as early as 5 min after
PHA (3 g/ml) treatment, reached the highest peak at 10 min, and
continuously decreased until 60 min. Interestingly, however,
PKC activation did not appear in the Jurkat transfectants express-
ing KIR (Fig. 9A). Similar phenomena were observed in the case
of PKC. PKC was activated in control Jurkat cells after PHA
treatment, but not in Jurkat transfectants expressing KIR (Fig. 9B).
Recombinant KIR cytoplasmic tail partially blocks the in vitro
PKC activation induced by phosphatidylserine and
diacylglycerol
We observed that KIR constitutively interacted with PKC and that
KIR appeared to inhibit PKC activation. To confirm the latter ob-
servation, an in vitro kinase assay was performed using 100 M
biotinylated PKC-selective synthetic peptide in the presence of a
bacterially expressed His-tag fusion protein of the p70 KIR cyto-
plasmic tail. PKC proteins were prepared from resting Jurkat T
cells by immunoprecipitation and were activated by adding phos-
phatidylserine and DAG in either the presence or the absence of
the recombinant KIR cytoplasmic tail protein. As shown in Fig.
9C, the recombinant KIR cytoplasmic tail protein appeared to in-
hibit, in a dose-dependent manner, the PKC activation induced
by phosphatidylserine and DAG treatments. In the presence of 10
M recombinant KIR cytoplasmic tail protein, total PKC activity
was decreased by 20%. However, BSA treatment did not affect
PKC activation. This implies that the cytoplasmic tail of KIR
possesses the potential to inhibit PKC activation.
Discussion
To better understand the immunological function of KIR in T cells,
we investigated the effect of KIR expression on AICD and its
signaling mechanism in Jurkat T cells. In this study we have shown
for the first time that KIR expressed on the surface of Jurkat T cells
inhibits the AICD induced by PHA, PMA/ionomycin, or cross-
linking of TCR/CD3 in a ligation-independent manner. The AICD
inhibition mediated by KIR appears to be due to the blockade of
FasL induction after the activation stimuli, and the membrane-
proximal 20 aa of the KIR cytoplasmic tail have been found to play
a crucial role in this process. Interestingly, in the membrane-prox-
imal portion of the KIR cytoplasmic tail, there exists a putative
PKC substrate site that includes a strictly conserved serine residue.
Based on this sequence information, we investigated whether KIR
recruits PKCs and how it affects the PKCs activation after PHA
stimulation. As expected, immunoprecipitation analysis demon-
strated that KIR constitutively binds both to PKC, a conventional
Ca2-dependent PKC, and to PKC, a novel Ca2-independent
PKC. Furthermore, an in vitro kinase assay revealed that PKC
activation is blocked after PHA stimulation in Jurkat transfectants
FIGURE 8. PKC and PKC are constitutively bound to the KIR cy-
toplasmic tail before and after activation stimuli. A, Immunoprecipitation
analysis of PKC. B, Immunoprecipitation analysis of PKC. Jurkat trans-
fectants expressing CD8KIR and CD8T constructs (5  107 cells) were
stimulated either with or without PMA (100 ng/ml) and ionomycin (1 g/
ml; P/I) for the indicated time periods, and then lysed in lysis buffer. These
cells were immunoprecipitated (IP) with mouse anti-CD8 mAb and washed
six times with lysis buffer. The immunoprecipitates were resolved in the
SDS-PAGE gels and blotted (Western blot) with either anti-PKC (A) or
anti-PKC (B) Abs. Aliquots of each immunoprecipitate were blotted with
rabbit polyclonal anti-CD8 Ab as the IP control, shown in the lower panel.
The results shown are representative of three independent experiments.
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expressing KIR. These observations were supported by establish-
ing that a bacterially expressed recombinant KIR cytoplasmic tail
also appeared to inhibit PKC activation in vitro. Taken together,
these data strongly suggest that KIR inhibits the AICD of T cells
by blocking FasL induction upon stimulation, in a process that
seems to be accomplished by PKC recruitment to the membrane-
proximal PKC binding site and subsequent inhibition of PKC ac-
tivation against the activating stimuli.
It seems a little contradictory that KIR-expressing Jurkat clones
reached a lower plateau cell density in growth curve than control
cells (Fig. 1B), although they were more resistant to AICD induced
by PHA, anti-CD3 mAb, or PMA/ionomycin (Figs. 2 and 6). One
simple, plausible explanation is to suppose that KIR-expressing
cells expend nutrients more quickly, since the cells appear to be
larger than control cells (Fig. 1C). The observation that KIR-ex-
pressing cells and control cells grow at a similar pace during the
log phase supports this idea (Fig. 1B). Alternately, it might be due
to a persistent down-modulation of PKC activities in KIR-express-
ing Jurkat. According to our results (Fig. 9), the expression of KIR
inhibits PKC activation in a ligation-independent manner, and thus
it could affect plateau cell densities of KIR-expressing Jurkat. In
fact, PKC isoforms have been implicated to affect the cell densities
of Swiss 3T6 fibroblasts and C6 glioma cells (62, 63).
It is well known that the cytotoxic function of killer cells is
inhibited by KIR expressed on NK cells and on some cytotoxic T
cells via the specific recognition of class I MHC molecules located
on target cells (1, 2, 8, 15). This ligation-dependent inhibitory
effect displayed by KIR is accomplished by phosphorylation of a
tyrosine residue(s) in the cytoplasmic tail of KIR and by subse-
quent recruitment of the SH2 domain-containing protein tyrosine
phosphatases, Src homology 2 domain-containing protein tyrosine
phosphatase-1/2 to the ITIM motifs (8, 9). The results of this study
indicate that KIR expressed on Jurkat T cells inhibits the AICD of
these cells in a ligation-independent manner. Interestingly, this in-
hibitory function demonstrated by KIR on T cell AICD appears to
be mediated by the putative PKC phosphorylation site at the mem-
brane-proximal region of the KIR cytoplasmic tail, a location far
from the ITIM motifs. Therefore, it is highly likely that KIR func-
tions as a negative regulator of T cell cytotoxicity and AICD
through two distinct mechanisms that are for the former ligation
dependent and for the latter ligation independent. The functional
significance of the membrane-proximal region of KIR in T cell
AICD is reminiscent of that of CTLA-4, in which the membrane-
proximal region is critical for operation of the receptor’s inhibitory
role in T cells (64), although the function and working mechanism
of the regions are quite different.
Three putative PKC substrate sites exist at the cytoplasmic tail
of p70 KIR, and the membrane-proximal one appears to be critical
for the inhibition of PKC activation. The membrane-proximal PKC
FIGURE 9. PKC activation is blocked by the KIR cytoplasmic tail. A
and B, Activation of PKC (A) and PKC (B) induced by PHA treatment
in the Jurkat clone expressing KIR and wild-type Jurkat. Cells (1 107) of
Jurkat and Jurkat clone expressing KIR (p701A1) were stimulated with 3
g/ml PHA for the indicated periods of time. Cells were lysed, and PKC
and PKC were immunoprecipitated. Immunoprecipitates equivalent to
2  106 cell lysates were subjected to an in vitro kinase assay using a
biotinylated PKC-selective synthetic peptide (NH2-AAKIQASFRGHMA
RKK-COOH in the single-letter amino acid code) as described in Materials
and Methods. The upper panel indicates PKC activity presented as the fold
increases compared with buffer-treated control cells. The average values of
three independent experiments are shown, and the error bar represents the
SD. The lower panels are Western blots of the PKC and PKC immu-
noprecipitates that were used in the kinase assay. C, Effect of the recom-
binant KIR cytoplasmic tail on the in vitro PKC activation induced by
phosphatidylserine (PS) and DAG. PKC immunoprecipitates were pre-
pared from resting Jurkat T cells and in vitro activated by treatment with
phosphatidylserine (0.32 mg/ml) and DAG (0.032 mg/ml) in either pres-
ence or the absence of the recombinant KIR cytoplasmic tail (KIR-cyt) at
concentrations from 0.1–10 M. An in vitro kinase assay was performed
with 100 M biotinylated PKC-selective synthetic peptide. BSA was used
as a control protein. An in vitro PKC assay was performed as described in
Materials and Methods. The other two clones (p702A6 and p704D2)
showed similar results.
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site displays a 100% sequence homology with all types of inhib-
itory KIR reported to date even with activating KIR forms that lack
ITIM in the cytoplasmic tail (5). Furthermore, a strictly conserved
cysteine residue is located next to the serine residue of the mem-
brane-proximal PKC site (Fig. 7A). Thus, the primary structural
features of the membrane-proximal PKC site are highly analogous
to the N-myristylated PKC peptide analog that is frequently used
for the inhibition of PKC activation in vitro (65). This peptide
analog is known as an irreversible PKC inhibitor in which a cys-
teine residue is substituted for the phosphorylable threonine resi-
due. It has been suggested that the covalent linkage between the
cysteine residue of the peptide analog and that of the PKC active
site induces irreversible inactivation of PKC in vitro (65). In the
present study we have postulated that a similar mechanism might
be involved in PKC inhibition by the KIR cytoplasmic tail, and our
data suggest that this tail may directly inhibit PKC activation
through the membrane-proximal PKC binding site. However, the
possibility that the KIR cytoplasmic tail might function as a com-
petitive substrate inhibitor, since it has three putative PKC phos-
phorylation sites, cannot be excluded at this stage.
PKC isoenzymes function as important signaling molecules that
regulate many transcription factors acting on the FasL promoter. In
particular, PKC participates in NF-B activation through activa-
tion of IB kinase  (66), functions as a selective upstream reg-
ulator of c-Jun N-terminal kinase (67) and consequently regulates
AP-1 activation (68), and affects NF-AT activation in cooperation
with calcineurin (47). PKC has also been implicated in the acti-
vation of ERK (69). We also observed that NF-AT promoter ac-
tivity was almost completely blocked, and ERK-1/2 activations
were significantly decreased when the Jurkat transfectants express-
ing KIR were stimulated with either PHA or anti-CD3 Ab (our
unpublished observations). These results support the hypothesis
that KIR inhibits FasL induction through the inhibition of PKC
activation.
PKC is known to play an important role in Fas-mediated apo-
ptosis as well as in T cell activation and AICD (46–48). Interest-
ingly, PKC appears to protect T cells from Fas-mediated apoptosis
either through phosphorylation of Bad (70, 71) or through modu-
lation of K loss and cell shrinkage (72). These findings provide
a molecular mechanism to explain our observation that Jurkat
transfectants expressing KIR appeared to be more susceptible than
control Jurkat T cells to Fas-mediated apoptosis (Fig. 4B). Sup-
pression of PKC activity by KIR might result in the inhibition of
Bad phosphorylation and/or the modulation of K loss and cell
shrinkage, and consequently cause the KIR-expressing Jurkat
transfectants to become more susceptible to Fas-mediated apopto-
sis. It is possible that although this phenomenon has a harmful
effect on KIR T cells when they encounter cells expressing FasL,
such as some tumor cells, the effect may be ameliorated by the
ligation-dependent activation of phosphoinositol 3-kinase via
ITIM motifs, as previously suggested by Marti et al. (10).
KIR  T cells are preferentially found within Ag-experienced
subsets, such as memory T cells and effector T cells (18, 24, 25).
This suggests that KIR is selectively induced during in vivo T cell
activation, and the KIR T cells selectively survive after T cell
responses. In fact, KIR appears to be expressed on T cells after
TCR gene rearrangement (11). Recently, Huard et al. (73) have
reported that the expression level of KIR on T cells is dynamically
regulated through TCR-mediated up-regulation and KIR-mediated
down-regulation. In agreement with this finding, the inhibitory ef-
fects of KIR on T cells have been shown to be unexpectedly com-
plex (8, 74). Therefore, it seems likely that the specific time point
and expression level of T cell surface KIR are the two important
variables in KIR functioning, especially for ligation-independent
PKC inhibition via KIR.
In summary, we have demonstrated here that KIR inhibits the
AICD of Jurkat T cells in a ligation-independent manner via the in-
hibition of FasL induction, in a process that seems to be mediated by
the inhibition of PKC activation through the membrane-proximal re-
gion of the KIR cytoplasmic tail rather than ITIM motifs. A focus for
future studies will be the elucidation of the exact molecular mecha-
nisms of KIR-mediated PKC inhibition, thereby increasing our un-
derstanding of the complex roles played by KIR in T cells.
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